Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in Germany - insights from the reload study

被引：0
|
作者：
Bonnemeier, H. [1 ]
Mundhenke, M. [2 ]
Von Mach, T. [2 ]
Huelsebeck, M. [2 ]
机构：
[1] Univ Med Ctr Schleswig Holstein, Dept Electrophysiol & Rhythmol, Kiel, Germany
[2] Bayer Vital GmbH, Leverkusen, Germany
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P3581
引用
收藏
页码：765 / 765
页数：1
相关论文
共 50 条
  • [31] Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation
    Murakawa, Yuji
    Ikeda, Takanori
    Ogawa, Satoshi
    Kitazono, Takanari
    Nakagawara, Jyoji
    Minematsu, Kazuo
    Miyamoto, Susumu
    Hayashi, Yasuhiro
    Kidani, Yoko
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Sato, Shoichiro
    Yamanaka, Satoshi
    HEART AND VESSELS, 2020, 35 (08) : 1125 - 1134
  • [32] Effectiveness and Safety of Dabigatran and Warfarin in Real-World US Patients With Non-Valvular Atrial Fibrillation: A Retrospective Cohort Study
    Lauffenburger, Julie C.
    Farley, Joel F.
    Gehi, Anil K.
    Rhoney, Denise H.
    Brookhart, M. Alan
    Fang, Gang
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (04):
  • [33] Medication adherence to rivaroxaban and dabigatran for stroke prevention in patients with non-valvular atrial fibrillation in the United States
    Coleman, Craig I.
    Tangirala, Muralikrishna
    Evers, Thomas
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 212 : 171 - 173
  • [34] Economic evaluation of rivaroxaban versus acenocoumarol in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain
    Rubio-Terres, C.
    Graefenhain De Codes, R.
    Rubio-Rodriguez, D.
    Evers, T.
    Grau, S.
    Espinos, B.
    Llorac, A.
    EUROPEAN HEART JOURNAL, 2016, 37 : 482 - 483
  • [35] How to REVISIT the increasing "real world" evidence for stroke prevention in non-valvular atrial fibrillation?
    Lip, Gregory Y. H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (12) : 2055 - 2057
  • [36] Comparative Effectiveness and Safety of Rivaroxaban and Warfarin for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in an Omani Tertiary Care Hospital
    Al-Maawali, Maya Said
    Al-Naamani, Hamed Hilal
    Mokadem, Leila Neshat
    Al-Maawali, Ghalib
    Salman, Bushra
    Al-Zakwani, Ibrahim
    OPEN CARDIOVASCULAR MEDICINE JOURNAL, 2022, 16
  • [37] Therapeutic compliance with rivaroxaban in preventing stroke in patients with non-valvular atrial fibrillation: CUMRIVAFA study
    Marquez-Contreras, Emilio
    Martell-Carlos, Nieves
    Gil-Guillen, Vincente
    De la Figuera-Von Wichmann, Mariano
    Sanchez-Lopez, Eugenio
    Marquez-Rivero, Sara
    Gil-Gil, Ines
    Hermida-Campa, Enrique
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (12) : 2013 - 2020
  • [38] Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
    Calderon, Jose Miguel
    Martinez, Fernando
    Diaz, Javier
    Fernandez, Antonio
    Sauri, Inmaculada
    Uso, Ruth
    Trillo, Jose Luis
    Vela, Sara
    Bea, Carlos
    Redon, Josep
    Forner, Maria Jose
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 8
  • [39] CHOICE OF ANTITHROMBOTIC DRUG IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN REAL-WORLD PRACTICE
    Citarella, A.
    Cammarota, S.
    Creazzola, S.
    De Marino, C.
    Izzo, P.
    La Bella, G.
    Piscitelli, R.
    Romagnuolo, F.
    Esposito, E.
    Guida, A.
    VALUE IN HEALTH, 2015, 18 (07) : A380 - A380
  • [40] Suboptimal Management of Patients with Non-valvular Atrial Fibrillation: Real-world Clinical Setting
    Lau, Wallis C. Y.
    Chan, Esther W.
    Wong, Ian C. K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 380 - 380
12345